SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 85 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $52,000 | -63.1% | 2,256 | -62.2% | 0.00% | – |
| Q4 2020 | $141,000 | +176.5% | 5,961 | +95.6% | 0.00% | – |
| Q3 2020 | $51,000 | -16.4% | 3,048 | -23.1% | 0.00% | – |
| Q2 2020 | $61,000 | +238.9% | 3,962 | +109.9% | 0.00% | – |
| Q1 2020 | $18,000 | -56.1% | 1,888 | -59.6% | 0.00% | – |
| Q4 2019 | $41,000 | +41.4% | 4,677 | +20.4% | 0.00% | – |
| Q3 2019 | $29,000 | -19.4% | 3,885 | +1.6% | 0.00% | – |
| Q2 2019 | $36,000 | +3500.0% | 3,824 | +1923.3% | 0.00% | – |
| Q4 2018 | $1,000 | 0.0% | 189 | +96.9% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 96 | -8.6% | 0.00% | – |
| Q2 2018 | $1,000 | -99.4% | 105 | -99.1% | 0.00% | – |
| Q2 2017 | $158,000 | – | 11,329 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |